Buchumschlag

Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine

Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver stages and the disease-causing blood stages of the human malaria parasite Plasmodium falciparum. While substantial progress has been made towards liver stage vaccines, the development of a blood stage vacci...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rosenkranz, Micha (VerfasserIn) , Fürle, Kristin (VerfasserIn) , Hibbert, Julia (VerfasserIn) , Ulmer, Anne (VerfasserIn) , Ali, Arin (VerfasserIn) , Giese, Thomas (VerfasserIn) , Blank, Antje (VerfasserIn) , Haefeli, Walter E. (VerfasserIn) , Böhnlein, Ernst (VerfasserIn) , Lanzer, Michael (VerfasserIn) , Thomson-Luque, Richard (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2023
In: npj vaccines
Year: 2023, Jahrgang: 8, Pages: 1-17
ISSN:2059-0105
DOI:10.1038/s41541-023-00701-2
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41541-023-00701-2
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41541-023-00701-2
Volltext
Verfasserangaben:Micha Rosenkranz, Kristin Fürle, Julia Hibbert, Anne Ulmer, Arin Ali, Thomas Giese, Antje Blank, Walter E. Haefeli, Ernst Böhnlein, Michael Lanzer and Richard Thomson-Luque
Beschreibung
Zusammenfassung:Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver stages and the disease-causing blood stages of the human malaria parasite Plasmodium falciparum. While substantial progress has been made towards liver stage vaccines, the development of a blood stage vaccine is lagging behind. We have recently conducted a first-in-human clinical trial to evaluate the safety and immunogenicity of the recombinant, full-length merozoite surface protein 1 (MSP1FL) formulated with GLA-SE as adjuvant. Here, we show that the vaccine, termed SumayaVac-1, elicited both a humoral and cellular immune response as well as a recall T cell memory. The induced IgG and IgM antibodies were able to stimulate various Fc-mediated effector mechanisms associated with protection against malaria, including phagocytosis, release of reactive oxygen species, production of IFN-γ as well as complement activation and fixation. The multifunctional activity of the humoral immune response remained for at least 6 months after vaccination and was comparable to that of naturally acquired anti-MSP1 antibodies from semi-immune adults from Kenya. We further present evidence of SumayaVac-1 eliciting a recallable cellular cytotoxicity by IFN-γ producing CD8+ T cells. Our study revitalizes MSP1FL as a relevant blood stage vaccine candidate and warrants further evaluation of SumayaVac-1 in a phase II efficacy trial.
Beschreibung:Veröffentlicht: 09. August 2023
Gesehen am 27.09.2023
Beschreibung:Online Resource
ISSN:2059-0105
DOI:10.1038/s41541-023-00701-2

Ähnliche Einträge